Fasting glucose and postprandial glycemia: Which is the best target for improving outcomes? The apollo and 4-T trials

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 16, 2008, Pages 2857-2865

  Monnier, Louis ^a   Colette, Claude ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Basal and prandial insulin regimens; Type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; LONG ACTING DRUG; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADD ON THERAPY; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET RESTRICTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; FASTING; GLUCOSE; HUMANS; HYPOGLYCEMIA; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 56749091099     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.16.2857     Document Type: Review

References (39)

1. Riddle MC. Evening insulin strategy. Diabetes Care 1990;45:32-6
2. Monnier L, Colette C, Lapinski H, Boniface H. Self-monitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple. Diabetes Metab 2004;20:113-9
3. 1c. JAMA 2006;295:1688-97
4. Monnier L, Colette C, Boegner C, et al. Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom? Diabetes Metab 2007;33:247-52
5. Dinneen S, Gerich JE, Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:707-13
6. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
7. Monnier L, Colette C, Boniface H. Contribution of postprandial glucose to chronic hyperglycaemia: from the 'glucose triad' to the trilogy of 'sevens'. Diabetes Metab 2006;32:2S11-2S16
8. Monnier L, Colette C. Glycemic variability. Should we and can we prevent it? Diabetes Care 2008;31(Suppl 2):S150-4
9. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of postprandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006;49:846-54
10. 1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-8
11. Avignon A, Radaceanu A, Monnier L. Non fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997;20:1822-6
12. 1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24:2023-9
13. 1c. Diabetes Care 2003;26:881-5
14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(Suppl 1):S5-20
15. Monnier L, Colette C, Rabasa-Lhoret R, et al. Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002;25:737-41
16. Buckingham B, Block J, Wilson DM. Continuous glucose monitoring. Curr Opin Endocrinol Diabetes 2005;12:273-9
17. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. Diabetes Care 2007;30:263-9
18. International Diabetes Federation. Guideline for Management of Postmeal Glucose. Brussels: IDF; 2007. p. 1-27
19. Lebovitz HE, Austin MM, Blonde L, et al. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006;12(Suppl 1):6-12
20. Bolli GB, Gerich JE. The dawn phenomenon: a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984;310:746-50
21. Boden G, Chen X, Urbain JL. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 1996;45:1044-50
22. American Diabetes Association. Standards of medical care in diabetes 2008. Diabetes Care 2008;31(Suppl 1):S12-54
23. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effect of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
25. Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006;32:7-13
26. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:494-5
27. Malone JK, Bai S, Campaigne BN, et al. Twice daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 2005;22:374-81
28. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 Study). Diabetes Obes Metab 2006;8:58-66.s
29. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
30. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus three daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial. Lancet 2008;371:1073-84
31. Scholtz HE, Pretorius SC, Wessels DH, Becker RHA. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycemic clamp technique. Diabetologia 2005;98:1988-95
32. Danne T, Lüpke K, Walte K, et al. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003;26:3087-92
33. Lepore M, Pampanelli S, Fanelli C, et al. Pharmaco-kinetics and pharmacodynamics of subcutaneaous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8
34. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20
35. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (position statement). Diabetes Care 2002;25:750-86
36. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET Study. Diabetologia 2006;49:442-51
37. 1c measurements be reported? Diabetologia 2006;49:7-10
38. Wolever TM, Yang M, Zeng XY, et al. Food glycemic index, as given in glycemic index tables, is a significant determinant of glycemic responses elicited by composite breakfast meals. Am J Clin Nutr 2006;83:1306-12
39. [125]I-labelled insulin glargine (HOE 901) in healthy men. Diabetes Care 2000;23:813-9